Nuwellis, Inc. Announces Proposed Underwritten Public Offering of Common Stock
15 September 2021 - 6:03AM
Nuwellis, Inc. (NASDAQ:NUWE) (the “Company”) announced today that
it intends to offer shares of its common stock in an underwritten
public offering. All of the shares of common stock to be sold
in the offering will be offered by the Company. The Company
intends to grant the underwriters a 45-day option to purchase up to
an additional 15% of the shares of its common stock offered in the
public offering. The Company intends to use the net proceeds
for the offering for general corporate purposes, including the
continued investment in commercialization efforts. The offering is
subject to market and other conditions and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Ladenburg Thalmann & Co. Inc. is acting as
sole book-running manager in connection with the offering.
The offering is made pursuant to a “shelf”
registration statement on Form S-3 (File No. 333-256797) that was
filed by the company with the Securities and Exchange Commission
(“SEC”) and was declared effective on July 2, 2021. The
Company will file a prospectus supplement with the SEC relating to
such shares of common stock. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to and
describing the terms of the offering may be obtained, when
available, at the SEC’s website at www.sec.gov or from Ladenburg
Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, NY
10019, or by email at prospectus@ladenburg.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. Any offer, if at
all, will be made only by means of the prospectus supplement and
accompanying prospectus forming a part of the effective
registration statement.
About Nuwellis Nuwellis, Inc.
(Nasdaq:NUWE) is a medical device company dedicated to changing the
lives of patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing, and commercializing the Aquadex
SmartFlow® system for ultrafiltration therapy. Nuwellis is
headquartered in Minneapolis, Minn., with a wholly-owned subsidiary
in Ireland.
About the Aquadex SmartFlow
System The Aquadex SmartFlow® system delivers clinically
proven therapy using a simple, flexible and smart method of
removing excess fluid from patients suffering from hypervolemia
(fluid overload). The Aquadex SmartFlow® system is indicated for
temporary (up to 8 hours) or extended (longer than 8 hours in
patients who require hospitalization) use in adult and pediatric
patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the closing of the offering of
securities and the anticipated use of the net proceeds therefrom.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, the uncertainties related
to market conditions and the completion of the public offering on
the anticipated terms or at all, those risks associated with our
ability to execute on our commercial strategy, the possibility that
we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. The Company does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:
George Montague
Chief Financial Officer, Nuwellis, Inc.
ir@nuwellis.com
Matt Bacso, CFA
Gilmartin Group LLC
Matt.bacso@gilmartinir.com
MEDIA:
Jessica Stebing
Health+Commerce
jstebing@healthandcommerce.com
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Newellis (NASDAQ:NUWE)
Historical Stock Chart
From Jul 2023 to Jul 2024